The following information is obtained from various newswires,
published medical journal articles, and medical conference presentations.
Company: Wyeth-Ayerst Laboratories
Approval Status: Approved July 1996
Treatment for: rheumatoid arthritis
General Information
Lodine has been approved for the treatment of rheumatoid arthritis. Lodine is a nonsteroidal anti-inflammatory drug (NSAID).
At the same time the FDA has cleared for market a new 500 mg dosage strength.
Clinical Results
The safety and efficacy of Lodine in relieving the signs and symptoms of rheumatoid arthritis were established in a three-year, double-blind, multicenter clinical trial involving 1,446 subjects with active rheumatoid arthritis. Data from the study indicated that doses of Lodine at 1,000 mg/day were efficacious and well tolerated in subjects being treated for active rheumatoid arthritis.
Literature References
Lanza F, Rack MF, Lynn M et al. "An endoscopic comparison of the effects of etodolac, indomethacin, ibuprofen, naproxen, and placebo on the gastrointestinal mucosa." J Rheumatology 1987; 14:338-341.
